UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 8, 2024, Sailaja Puttagunta M.D. notified Iterum Therapeutics plc (the “Company”) of her decision to resign as Chief Medical Officer the Company, effective May 31, 2024. Dr. Puttagunta’s resignation is due to personal reasons and not a result of any disagreement with the Company. Dr. Puttagunta has agreed to work with the Company as a consultant, on terms yet to be determined, throughout the regulatory review period of the Company’s recently resubmitted new drug application for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women.
Item 8.01 Other Events.
Steven Aronin, M.D., the Company’s current Senior Vice President and Head of Clinical Development, will lead the Company’s development and regulatory activities following the effective date of Dr. Puttagunta’s resignation.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Iterum Therapeutics plc |
|
|
|
|
Date: |
May 10, 2024 |
By: |
/s/ Corey N. Fishman |
|
|
|
Chief Executive Officer |
Document And Entity Information |
May 10, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | May 10, 2024 |
Entity Registrant Name | Iterum Therapeutics plc |
Entity Central Index Key | 0001659323 |
Entity Emerging Growth Company | false |
Entity File Number | 001-38503 |
Entity Incorporation, State or Country Code | L2 |
Entity Tax Identification Number | 00-0000000 |
Entity Address, Address Line One | Fitzwilliam Court |
Entity Address, Address Line Two | 1st Floor |
Entity Address, Address Line Three | Leeson Close |
Entity Address, City or Town | Dublin 2 |
Entity Address, Country | IE |
Entity Address, Postal Zip Code | Not applicable |
City Area Code | +353 |
Local Phone Number | 1 6694820 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Ordinary Shares, par value $0.01 per share |
Trading Symbol | ITRM |
Security Exchange Name | NASDAQ |
_P'Y 7:L7R%@7_]EF=VVGX[ @
MUT8F^V D2$2Z^^4?^T0CFMTHAEI$
M(YQ([:S,C<*S N/,Z%X&.2;9L'$:LH?4"+-ETW0WVYBU0 -8?20$3;8T.P6BP^0"X99K>]9!:G
04!
M+/N^@Y3W'<\TW6